वीनस रेमेडीज > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का वीनस रेमेडीज - बीएसई: 526953, NSE: VENUSREM

वीनस रेमेडीज

बीएसई: 526953  |  NSE: VENUSREM  |  ISIN: INE411B01019  |  Pharmaceuticals

कंपनी इतिहास - वीनस रेमेडीज
M/s VENUS REMEDIES LTD. was incorporated as a private limited company
 on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt
 Ltd, and subsequently converted into a public limited company, vide
 fresh certificate of incorporation dated 19th Sept. 1994 and the name
 converted as Venus Remedies Ltd under the Companies Act, issued by
 the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh
 at Jalandhar.  The company started its production in the year 1991
 Intravenous/Intramuscular (IV/IM) injectable forms at its running
 unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala
 (Haryana).  Subsequently the company introduced Eye/Ear/Nasal Drops
 during the year 1994.  During the same year, the company also
 expanded its existing
 capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and
 that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section
 and vial section respectively.  And, during 1994, the company has also
 certified as WHO-GMP (Good practices in manufacturing and quality
 control) as specified by WHO, Geneva by the State Drug Controller of
 The main objects of the company as set out in its Memorandum of
 Association are :
 1. To manufacture, import, export of intravenous transfusion fluids
 and formations such as dextrose, dextrose with sodium chloride,
 normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol
 etc. in various concentrations, intravenous solution for dialysis
 ACD Sterile bottles for blood collections, pharmaceutical parenteral
 preparations like Aminophylline, Adernaline, Water for injection,
 Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam,
 Oxyphenbutazone & other injectables.
 2. To carry on the business of deriving, formulating, purchasing,
 producing manufacturing, preparing, processing, mising, compounding,
 refining, marketing, distributing, selling and trading in
 pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs
 of all kinds, specifications and descriptions, and to do so
 especially in
 respect of all kinds of analgesics and antipyretics.
 3. To carry on the business of purchasing, producing manufacturing,
 preparing, processing, mixing, compounding, refining, marketing,
 distributing, selling and trading in all classes and kinds of raw
 material ingredients, mixtures, compounds and derivatives connected
 intermediate in or associated with the manufacture production and
 sale of pharmaceuticals, chemicals medicines and drugs.
 4. To carry on the business of vialling, bottling, packing. repacking
 and processing of capsules, syrups, tablets, injectables, aerosoles
 and ointment, bulk drugs and chemicals.
 -Venus Remedies successfully launches its Brand Ronem
 -Venus Remedies announces Strategic Marketing tie up with M/S Cadila
 Pharmaceuticals Ltd
 - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up
 with Venus Remedies Ltd.
 -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock
 -Venus Remedies has entered into Strategic Marketing Agreement with
 Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd,
 Darmstadt, Germany, for its Oncology range of products.
 -Venus Remedies sets up a wholly owned subsidiary in Germany
 -Venus Remedies Ltd has informed that a Company has been granted
 three prestigious ISO certifications
 -Venus Remedies in-licenses product Technology from USA
 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match
 R&D B.V. a limited Company based at Amsterdam, Netherlands for
 jointly preparing, registering and marketing an EU E-CTD Dossier for
 a latest generation Carbapenem Injectible.
 -Venus facilities Accredited with European GMP Certification.
 -Venus Remedies Ltd has informed that the Company's manufacturing
 facilities have been approved by the G.F.T.O of Syria for
 manufacturing and exporting its products to Syria.
 -Venus Remedies - European AMP Accreditation for Venus Oncology
 -Venus Remedies Ltd has informed that the Company has successfully
 launched its fourth Research Product, a Fixed Dose Combination of
 Cephalosporin with aminoglycoside under the
 Brand name TOBRACEF in Domestic Market for the first time globally.
 -Venus Remedies - Product Patent for TOBRACEF granted in South
 -Venus Bags Another Product Patent from South Africa for POTENTOX.
 --Registered Office of the Company has been shifted  from SCO 39,
 Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC
 Manimajra, Chandigarh - 160 101.
 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the
 country, has launched MEBATIC, a unique antibiotic combination in
 infusion form to cure severe gastro intestinal (GI) infections.
 -Venus Remedies receives GMP Certification from Botswana.
 -Venus Remedies ties up with IMTECH and Panjab Univ to develop
 Typhoid detection kits.
 -The Company has received approval from the Reserve Bank of India for
 rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15,
 -Venus Remedies research Blockbuster Sulbactomax gets European Union
 -Venus Remedies Anti-Cancer drug GEMCITABINE gets UK MHRA approval.
 -Sulbactomax patent from Mexico strengthens Venus Remedies' presence
 in Latin America.
 -Venus Remedies successfully completes Phase I & II Clinical Trials
 of TUMATREK (VRP162O), cancer detection molecule.
 -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed
 Martin India Innovation Growth Program 2011.
 -Venus launches its patented research product ACHNIL in India.
 -Venus Remedies wins India Manufacturing Excellence Award 2011.
 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year
 -VenusRemedis - Innovative Solution for alleviating cancer.
 -Venus Remedies introduces Ready-to-Use Single Vial Taxedol in
 -Venus Remedies Limited introduced TROIS that is a research based,
 patent protected topical nano-emulsion product in India
 -The Company has won Manufacturing Award for its world class
 manufacturing and operational excellence at the Industry 2.0
 Manufacturing Innovation Conclave 2012.
 -Venus wins Patent award in Silver Category.
 -Venus Remedies launches Elores - CSE 1034, a US Patent projected
 product in India.
 -Venus Remedies signs MoU for Elores with South African
 pharmaceutical firm.
 -Venus Remedies takes its flagship product, Elores into Latin
 -Venus launches its first OTC product Ezenus.
 -Venus sign Exclusive Marketing Rights deal for its novel Antibiotic
 Ajuvant Entity to South Africas second largest Pharmaceutical Company
 - Adcock.
 -Venus Remedies MEROPENEM receives market authorization in Mexico.
 -Venus Remedies Ltd has informed regarding ELORES awarded Gold Medal
 for being the best Innovation of 2013
 -Venus wins Innovative 100 Award for ELORES.
 -Venus bags UBM India Pharma Award for Elores.
 -Venus ties up with Mylan for marketing meropenem in three European
 - VMRC Drug VRP008 to Fight MULTI-DRUG Resistant Bacteria Receives
 European Patent.
 -Venus Receives Market Authorization for Meropenem from SWITZERLAND
 -Venus announces issuance of Indian Patent for Vancoplus.
 -Venus Remedies holds blood, organ donation camps on its Panchkula
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • JEFFERIES ON MGL : BUY रेटिंग, लक्ष्य घटाकर `1180/Sh
  • CITI ON NMDC : BUY रेटिंग, लक्ष्य `125/Sh
  • MS ON ADANI PORTS : Overweight रेटिंग, लक्ष्य `408/Sh
  • CITI ON COAL INDIA : BUY रेटिंग, लक्ष्य बढ़ाकर `270/Sh
  • CITI ON MOTHERSON SUMI : Neutral रेटिंग, लक्ष्य बढ़ाकर `135/Sh
  • CITI ON BRITANNIA IND : BUY रेटिंग, लक्ष्य बढ़ाकर `3575/Sh
  • CITI ON INDIAN ECONOMY : Q2 में GDP ग्रोथ 4.9% रहने का अनुमान
  • CITI ON INDIAN ECONOMY : Q3 में ग्रोथ 6% के करीब रहने का अनुमान
  • HSBC ON IIP : IIP पर दबाव की स्थिति बरकरार
  • HSBC ON IIP : कैपिटल गुड्स में लगातार 5वें महीने गिरावट

अभी देखें

आवाज समाचार




(August 06, 2018)

AT (Rs)






Super Combo

Powerful mix of both trader and investor packs with timely expert advice.


Designed especially for traders looking to tap the profit opportunities of volatile markets.


For all investors looking to unearth stocks that are poised to move.